Rituximab in refractory Vogt-Koyanagi-Harada disease

Journal of Ophthalmic Inflammation and Infection

Volumn 1, Issue 4, 2011, Pages 177-180

  Dolz Marco, Rosa ^a   Gallego Pinazo, Roberto ^a   Díaz Llopis, Manuel ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Chronic VKH; Immunommodulators; Rituximab

Indexed keywords

ADALIMUMAB; CYCLOSPORIN; DEXAMETHASONE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID;

ADULT; ARTICLE; CASE REPORT; DRUG MEGADOSE; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HAND MOVEMENT; HEADACHE; HUMAN; OPTICAL COHERENCE TOMOGRAPHY; PLEOCYTOSIS; PRIORITY JOURNAL; RETINA DETACHMENT; TINNITUS; VISUAL ACUITY; VISUAL IMPAIRMENT; VOGT KOYANAGI SYNDROME;

EID: 84862996863     PISSN: None     EISSN: 18695760     Source Type: Journal    
DOI: 10.1007/s12348-011-0027-9     Document Type: Article

References (15)

1. Vasconcelos-Santos DV, Sohn EH, Sadda S, Rao NA (2010) Retinal pigment epithelial changes in chronic Vogt-Koyanagi-Harada disease. Retina 30: 33-41.
2. Díaz-Llopis M, Navea A, Peris C, Amselem L, Pinós J, Salom D, Hernández ML (2004) Síndrome de Vogt-Koyanagi-Harada, actualización. Studium Ophthalologicum 22: 157-166.
3. Inomata H, Rao NA (2001) Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131: 607-614.
4. Paredes I, Ahmed M, Foster CS (2006) Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm 14: 87-90.
5. Tappeiner C, Heinz C, Specker C, Heilighenhaus A (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 39: 184-186.
6. Freidlin J, Wong IG, Acharya N (2007) Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol 91: 1414.
7. Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, Goldberg RA, Darwin CH, Smith TJ, Douglas RS (2010) Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117: 133-139.
8. Miserocchi E, Pontikaki I, Modorati G, Bandello F, Meroni PL, Gerloni V (2011) Rituximab for uveitis. Ophthalmology 118: 223-224.
9. Read RW, Yu F, Accorinti M, Bodaghi B, Chee SP, Fardeau C, Goto H, Holland GN, Kawashima H, Kojima E, Lehoang P, Lemaitre C, Okada AA, Pivetti-Pezzi P, Secchi A, See RF, Tabbara KF, Usui M, Rao NA (2006) Evaluation of the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Am J Ophthalmol 142: 119-124.
10. Niccoli L, Nannini C, Cassarà E, Gini G, Lenzetti I, Cantini F (2009) Efficacy of infliximab therapy in two patients with refractory Vogt-Koyanagi-Harada disease. Br J Ophthalmol 93: 1553-1554.
11. Díaz Llopis M, Amselem L, Romero FJ, García-Delpech S, Hernández ML (2007) Adalimumab therapy for Vogt-Koyanagi-Harada syndrome. Arch Soc Esp Oftalmol 82: 131-132.
12. Khalifa Y, Loh AR, Acharya NR (2009) Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 17: 431-433.
13. Andrade RE, Muccioli C, Farah ME, Nussenblatt RB, Belfort R Jr (2004) Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 137: 572-574.
14. Park HS, Nam KY, Kim JY (2011) Intravitreal bevacizumab injection for persistent serous retinal detachment associated with Vogt-Koyanagi-Harada disease. Graefes Arch Clin Exp Ophthalmol 249: 133-136.
15. Piccio L, Naismith RT, Trinkaus K, Klein RS, Parks BJ, Lyons JA, Cross AH (2010) Changes in B-and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 67: 707-714.